RxDoctor Payments Data

Slava Kulakov, MD

Internal Medicine · Fairfield, CTNPI 1073524104

Payments from drug & device makers

$836in general payments, 2019–2025

Across 26 payments — averaging $32.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$250
  • Pfizer$175
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$140
  • Johnson & Johnson$130
  • Sumitomo Pharma America, Inc.$41
  • AbbVie$28
  • plus $72 from 4 others

What the payments were for

  • Food & beverage$83199%
  • Education$51%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$836 in reported general payments places this provider in the 75th percentile of 2,067 internal medicine providers in Connecticut.

See all internal medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$99,326
Medicare patients
262
Services billed
915

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin138$182,905
OzempicSemaglutide138$176,237
EliquisApixaban87$78,305
Trelegy ElliptaFluticasone/Umeclidin/Vilanter48$41,711
JanumetSitagliptin Phos/Metformin Hcl19$30,351
XareltoRivaroxaban18$30,288
JanuviaSitagliptin Phosphate18$26,826
MounjaroTirzepatide23$25,650
TrulicityDulaglutide15$24,443
Synjardy XrEmpagliflozin/Metformin Hcl27$22,346
MyrbetriqMirabegron17$14,608
LinzessLinaclotide12$9,769
Breo ElliptaFluticasone/Vilanterol12$7,147
Atorvastatin Calcium505$5,298
Omeprazole240$3,918

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy Xr$15$205,251165 claims
Novo NordiskOzempic$22$176,237138 claims
PfizerEliquis$175$78,30587 claims
GSKTrelegy Ellipta, Breo Ellipta$19$48,85860 claims
Johnson & JohnsonXarelto$130$30,28818 claims
AbbVieLinzess, Synthroid$28$12,16247 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,067 internal medicine providers in Connecticut.

Other internal medicine in Fairfield

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →